Transcriptional regulation of the urokinase receptor (u-PAR) - A central molecule of invasion and metastasis [PDF]
, 2003 The phenomenon of tumor-associated proteolysis has been acknowledged as a decisive step in the progression of cancer. This short review focuses on the urokinase receptor (u-PAR), a central molecule involved in tumor-associated invasion and metastasis ...
Fuchs, T., Allgayer, H.
core +1 more source
Tumor markers in breast cancer - European Group on Tumor Markers recommendations [PDF]
, 2005 Recommendations are presented for the routine clinical use of serum and tissue-based markers in the diagnosis and management of patients with breast cancer.
Einarsson, Roland +10 more
core +1 more source
Interdependence of kallikrein-related peptidases in proteolytic networks [PDF]
, 2010 Human kallikrein-related peptidases (KLKs) are 15 homologous serine proteases involved in several (patho)physiological processes, including cancer. Secreted as precursors, they are activated upon proteolytic release of a short propeptide. We searched for
Burkhart, Julia M. +27 more
core +1 more source
The structure of the urokinase-type plasminogen activator receptor gene [PDF]
Blood, 1994 The cellular receptor for urokinase-type plasminogen activator (uPAR) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that plays a central role in pericellular plasminogen activation. It contains 313 amino acid residues, including 28 cysteine residues in a pattern of three homologous repeats. The cysteine residue pattern suggests that
J R, Casey +4 more
openaire +3 more sources
Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer [PDF]
EJNMMI Research, 2020 AbstractThe urokinase plasminogen activator receptor (uPAR) plays a multifaceted role in almost any process where migration of cells and tissue-remodeling is involved such as inflammation, but also in diseases as arthritis and cancer. Normally, uPAR is absent in healthy tissues.
Baart, V.M. +6 more
openaire +4 more sources
Oncology Letters, 2017 The soluble urokinase-type plasminogen activator receptor (suPAR) and the urokinase-type plasminogen activator receptor (uPAR) have been proposed as useful biomarkers of tumor progression. Recently, suPAR was associated with chemoresistance in lung cancer. However, its clinical significance in leukemia has not previously been investigated.
Hong, Guo +6 more
openaire +3 more sources
Modulation of neuronal plasticity by extracellular serine proteases and their inhibitors : proteolytic control of NMDA receptors [PDF]
, 2004 Serine proteases are enzymes catalyzing protein cleavage. Because of their capability to cleave a wide variety of substrates, they are involved in many critical physiological processes such as digestion, hemostasis, reproduction and immune response, as ...
Kvajo, Mirna
core +1 more source
Urokinase-Type Plasminogen Activator Receptor: A Beacon of Malignancy? [PDF]
Clinical Cancer Research, 2008 Abstract Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies.
Ronny, Drapkin +2 more
openaire +2 more sources
suPAR na avaliação do prognóstico após permanência na unidade de terapia intensiva: um estudo piloto
Revista Brasileira de Terapia Intensiva, 2019 RESUMO Objetivo: Determinar o desempenho da dosagem do receptor ativador de plasminogênio tipo uroquinase solúvel quando da alta da unidade de terapia intensiva para predição da mortalidade após permanência na mesma unidade.
Joana Silvestre +5 more
doaj +1 more source
Site-specific chemoenzymatic labeling of aerolysin enables the identification of new aerolysin receptors. [PDF]
PLoS ONE, 2014 Aerolysin is a secreted bacterial toxin that perforates the plasma membrane of a target cell with lethal consequences. Previously explored native and epitope-tagged forms of the toxin do not allow site-specific modification of the mature toxin with a ...
Irene Wuethrich +7 more
doaj +1 more source